Loading...
XETRBIO
Market cap1.25bUSD
Dec 23, Last price  
41.40EUR
1D
0.00%
1Q
-0.48%
Jan 2017
160.38%
Name

Biotest AG

Chart & Performance

D1W1MN
XETR:BIO chart
P/E
14.82
P/S
2.75
EPS
2.79
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
11.33%
Revenues
685m
+32.65%
217,851,000000422,956,000440,191,000412,482,000422,027,000439,967,000500,800,000582,000,000589,600,000553,100,000378,100,000400,300,000419,100,000484,200,000515,600,000516,100,000684,600,000
Net income
127m
P
5,854,00000028,119,00028,020,00039,485,00048,149,00033,408,00032,000,00019,200,000-82,500,000-45,800,000-3,500,000181,700,000-4,700,000-31,400,000-63,300,000-31,600,000127,000,000
CFO
-3m
L-93.33%
25,291,00028,317,00026,307,00032,509,00034,489,00031,682,00077,828,00072,278,00034,726,000-7,200,000-11,400,00038,100,00065,900,00034,300,000-50,000,000-33,600,000-16,700,00033,900,000-40,500,000-2,700,000
Dividend
May 08, 20240.04 EUR/sh
Earnings
Mar 26, 2025

Profile

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
URL
https://www.biotest.com/
IPO date
Oct 14, 1987
Employees
2,307
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
684,600
32.65%
516,100
0.10%
515,600
6.48%
Cost of revenue
551,500
522,400
568,400
Unusual Expense (Income)
NOPBT
133,100
(6,300)
(52,800)
NOPBT Margin
19.44%
Operating Taxes
(20,700)
800
700
Tax Rate
NOPAT
153,800
(7,100)
(53,500)
Net income
127,000
-501.90%
(31,600)
-50.08%
(63,300)
101.59%
Dividends
(800)
(800)
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
260,100
9,400
6,400
Long-term debt
487,500
593,900
516,700
Deferred revenue
127,200
Other long-term liabilities
97,000
135,600
(1,900)
Net debt
601,200
481,600
414,200
Cash flow
Cash from operating activities
(2,700)
(40,500)
33,900
CAPEX
(33,400)
(29,300)
(18,200)
Cash from investing activities
1,300
(37,000)
(23,400)
Cash from financing activities
(6,800)
89,600
22,600
FCF
(28,300)
(62,200)
9,400
Balance
Cash
118,500
136,600
117,500
Long term investments
27,900
(14,900)
(8,600)
Excess cash
112,170
95,895
83,120
Stockholders' equity
279,100
151,300
160,600
Invested Capital
1,173,530
982,305
917,580
ROIC
14.27%
ROCE
10.35%
EV
Common stock shares outstanding
39,571
39,571
39,571
Price
Market cap
EV
EBITDA
169,000
29,500
(21,700)
EV/EBITDA
Interest
40,000
19,700
13,200
Interest/NOPBT
30.05%